LCA Lung Cancer Clinical Guidelines December 2013 LCA LUNG CANCER CLINICAL GUIDELINES Contents Introduction Executive Summary Prevention 1.1 Background information 1.2 Smoking cessation services 1.3 Implementation of smoking cessation guidance 10 Early Diagnosis 11 2.1 Referral and Diagnosis 12 3.1 Referral for suspected lung cancer 12 3.2 Assessment of patients with possible lung cancer for investigation 14 3.3 Diagnostic investigations 15 3.4 Staging investigations 16 3.5 Staging of lung cancer 18 Radiology 20 4.1 Standards to improve early diagnosis for lung cancer 11 Routine indications for imaging 20 Pathology Guidelines for the Reporting of Lung Cancer 23 5.1 Biopsies for lung cancer 23 5.2 Lung resection for tumours 23 5.3 Cytology specimens for lung cancer 23 5.4 Referral of difficult cases 24 5.5 Molecular analysis 24 MDT Membership and Function 25 Data Requirements of Lung Cancer Services 26 7.1 The Cancer Outcomes and Services Dataset (COSD) 26 7.2 National Audits – National Clinical Lung Cancer Audit (LUCADA) 26 7.3 Systemic Anti-Cancer Therapy (SACT) chemotherapy dataset 26 7.4 National Radiotherapy Dataset (RTDS) 26 7.5 National Cancer Waiting Times Monitoring Data Set 27 7.6 Local data requirements 27 Breaking Bad News 28 8.1 Advance preparation 28 8.2 Build a therapeutic environment 28 8.3 Communication 28 8.4 Dealing with reactions 28 CONTENTS 10 Inter-professional Communication between Secondary and Primary Care 30 9.1 General principles 30 9.2 At diagnosis 30 9.3 MDT discussions and decisions 31 9.4 Letters from clinics 31 9.5 Treatment Record Summary 31 Surgical Guidelines 32 10.1 Introduction 32 10.2 Non-small cell lung cancer 32 10.3 Risk assessment for surgery 32 10.4 Enhanced recovery after surgery (ERAS) 34 10.5 Lymph node management 34 10.6 Adjuvant therapy 34 10.7 Bronchopulmonary carcinoids 34 10.8 Small cell lung cancer 35 10.9 Post-operative follow-up 35 10.10 LCA high-quality lung cancer surgical service – measures and metrics 36 11 12 13 Non-surgical Management of Early Stage Non-small Cell Lung Cancer 38 11.1 Stereotactic ablative radiotherapy 38 11.2 Patient selection 38 11.3 Patient information and consent 39 11.4 Radiotherapy localisation imaging and contouring 39 11.5 Selection of optimal plan 41 11.6 Dose schedules 44 11.7 Treatment verification and delivery 44 11.8 Patient management during and following treatment 44 11.9 Percutaneous thermal tumour ablation (PTTA) 45 Management of Locally Advanced Non-small Cell Lung Cancer 46 12.1 Radical concomitant chemo-radiotherapy/sequential chemo-radiotherapy/ radiotherapy alone 46 12.2 Patient selection 46 12.3 Chemotherapy schedule 46 12.4 Radical radiotherapy 47 12.5 Patient management during and following treatment 47 Management of Metastatic Non-small Cell Lung Cancer 48 13.1 First-line chemotherapy 48 13.2 Second- and third-line chemotherapy 49 LCA LUNG CANCER CLINICAL GUIDELINES 14 15 16 17 13.3 Palliative radiotherapy 49 13.4 Follow-up of patients after treatment with palliative intent 50 Management of Small Cell Lung Cancer 51 14.1 Introduction 51 14.2 Limited stage disease 51 14.3 Extensive stage disease 52 Supportive and Palliative Care 53 15.1 Key stages for consideration of palliative care needs 53 15.2 Specific therapies 55 The Lung Cancer CNS/Key Worker 60 16.1 Team membership 61 16.2 Patient information 61 16.3 Holistic needs assessment 62 Lung Cancer Survivorship Guidelines 63 17.1 Discuss a person’s needs 64 17.2 Provide a treatment summary and care plan 64 17.3 Provide a main contact 64 17.4 Identify post-treatment symptoms 65 17.5 Provide support about day-to-day concerns 65 17.6 Talk about how you feel 65 17.7 Healthy lifestyle 65 17.8 Self-managed follow-up 67 17.9 Encourage survivors to share their experience 68 Appendix 1: Urgent Suspected Lung Cancer Referral Forms 69 Appendix 2: Systemic Anti-cancer Therapy in Lung Cancer 73 Appendix 3: SCLC Chemotherapy Regime – Oral Etoposide 74 Appendix 4: Radiotherapy: Radiotherapy Normal Tissue Delineation and Tolerances for Radical Treatment 75 Appendix 5: Competencies for Key Worker Role 76 Appendix 6: LCA Key Worker Policy 78 Appendix 7: LCA Holistic Needs Assessment Tool 81 Appendix 8: NCSI Treatment Summary 82 Appendix 9: Lung Pathway Metrics 85 Appendix 10: Treatment of Teenagers and Young Adults 86 Abbreviations 88 References 90 Acknowledgements 92 INTRODUCTION Introduction Lung cancer is the most common cause of death from cancer for males and the second most common cause of death for females (after breast cancer) The annual incidence of lung cancer in South East England is 54.5 per 100,000 among men and 27.8 per 100,000 among women (average standardised incidence rates, 1999–2003, Thames Cancer Registry) Mortality rates are almost as high, at 47.9 per 100,000 for men and 23.4 per 100,000 for women (average standardised mortality rates, 1999–2003, Thames Cancer Registry) Survival from lung cancer is poor, with less than 10% of patients surviving more than years The best chance of cure is with early diagnosis and surgery, but as it is so strongly related to smoking, no guidelines can be written without considering prevention and ensuring that all clinicians take the opportunity to give advice on smoking cessation, particularly to patients referred and reassured through the week wait pathway The National Lung Cancer Audit has been in place since 2006, and now that most Trusts are reliably entering data, it allows for an earlier comparison of surrogates for survival through data on the proportion of patients receiving potentially curative or active treatment It is therefore salutary to note that, in 2011, of patients with stages I and II non-small cell lung cancer, the percentage treated surgically varied between 21% and 62% depending on the Trust of diagnosis, for Trusts seeing at least 20 patients in this group If the London Cancer Alliance (LCA) were to be able to increase the percentage of these patients treated surgically to that of the best-performing Trust in this audit, then an additional 11% of patients in this group would receive surgical treatment For small cell lung cancer, there is a similar variation: the proportion of patients treated with chemotherapy according to Trust at presentation varies between 50% and 76%, for Trusts diagnosing at least 20 such patients per annum While there may be many reasons for these differences, the LCA needs to be assured that all patients are being diagnosed and staged in an agreed timeframe and managed to the same standards – hence the need to have LCA-agreed guidelines for the treatment of lung cancer Prior to the establishment of the LCA, the needs of lung cancer patients were managed and supervised by three cancer networks – north west, south west and south east London The LCA Lung Cancer Clinical Guidelines have combined the best aspects of the guidelines of the three networks, and have been updated to reflect changes and developments in practice The LCA guidelines are designed to be used by all healthcare professionals in Trusts within the LCA who are involved in the care of the lung cancer patient They have been developed to take into account the wide range of clinical experience of the user and the different clinical settings in which they work The guidelines are intended to assist in the initial assessment, investigation and management of patients Adoption of the LCA guidelines will allow widespread implementation of up-to-date and evidence-based management of lung cancer patients, and will assist in the provision of a consistently high standard of care across the LCA All Trusts are expected to be able to provide the standard of care detailed in these guidelines These guidelines will be reviewed on an annual basis in line with guidance from the National Institute for Health and Care Excellence, the British Thoracic Society, and other national and international guidance, as well as significant new research publications, to ensure that they continue to reflect best practice Please note that this set of guidelines is limited to small cell, non-small cell lung cancer, and carcinoid Separate clinical guidelines will be developed for mesothelioma and thymoma LCA LUNG CANCER CLINICAL GUIDELINES Please also note that treatment for patients from the age of 16 to their 25th birthday should be in line with national guidance regarding the management of teenagers and young adults with cancer Patients from the age of 16 to the end of their 18th year should be treated in a principal treatment centre (see Appendix 10 for contact details of principal treatment centres) Teenagers and young adults from the age of 19 to their 25th birthday will follow the adult pathway but should be offered choice of treatment in a teenage and young adult (TYA) designated hospital or at the principal treatment centre Teenagers and young adults in this age group should be treated either in the principal treatment centre or a designated hospital I hope these guidelines are helpful Many specialists both within the LCA Lung Pathway Group and the stakeholder group have contributed All members of the stakeholder group have had the opportunity to review the guidelines, and their comments have been taken into consideration I would like to thank them for their contributions Dr Liz Sawicka Consultant chest physician, Princess Royal University Hospital Chair, LCA Lung Pathway Group EXECUTIVE SUMMARY Executive Summary More than 80% of lung cancer deaths are attributable to smoking, and as many of the patients who are seen through the two week wait (2ww) clinics may fortunately not turn out to have cancer, the guidelines would not be complete if they did not deal with the issue of smoking cessation and interventions that could be successful in these patients, which are covered in Chapter Chapter 2, on early diagnosis, sets challenging improvements in availability of reports by radiologists of all chest X-rays of patients attending emergency departments This is not current practice in all district general hospitals at the present time It supports the NICE recommendation of CT scanning for patients referred through the week wait pathway prior to the first clinic appointment, to try to improve the time to diagnosis and treatment Early availability of the CT scan enables more accurate radiological diagnosis to be made at the first visit and influences the choice of biopsy site, supporting the implementation of latest NICE guidance which recommends that biopsies should be taken from sites of metastases where this is safer and will provide additional staging information The role of endo-bronchial ultrasound and biopsy of mediastinal nodes for staging of the disease is discussed in Chapter on referral and diagnosis, and choice of radiological test and biopsy technique are covered in Chapter The LCA supports the use of the minimum dataset recommendation of the Royal College of Pathologists for all specimens taken to establish or confirm the diagnosis of lung cancer, while the need for judicious use of sampled tissue to ensure that enough remains for molecular testing for gene mutations which influence subsequent choice of treatment is stressed in Chapter The membership and function of the multidisciplinary team (MDT) which makes decisions on diagnosis, stage and treatment of patients with lung cancer is discussed in Chapter It is essential to have a fully represented team participating in decision making to ensure that state-of-the-art treatment is offered to patients with the best chance of an improved outcome Furthermore, a fully functioning team is required to meet peer review standards, and this is supported by the LCA The need for data collection to measure outcomes is stressed in Chapter 7, and the collection thereof, in particular the clinical data, remains the responsibility of the members of the multidisciplinary team, with support from a data manager A summary of key information and guidance for staff dealing with patients and giving diagnoses of cancer is provided in Chapter In Chapter 9, guidance is given for ways of achieving good communication with patients and professionals in primary care and the community The Model of Care made three recommendations for lung cancer: that there should be a thoracic surgeon providing input to all lung cancer MDT patient management decisions, that thoracic surgical centres should serve a population in excess of million, and that these centres should perform a minimum of 60 resections a year including diagnostic and therapeutic lung cancer surgery These guidelines ensure that the first of these is met by all MDTs The LCA lung pathway group undertook an extensive review and confirmed that the other two standards are met by all centres as these serve large populations extending beyond the LCA, and as a result exceed the minimum surgical volumes LCA LUNG CANCER CLINICAL GUIDELINES Please note that the Model of Care recommended that the number of surgical centres should be reduced to ensure that all centres met these standards Based on the review it was agreed with the LCA Clinical Board, Members’ Board and NHS commissioners that there was no evidence for a reduction In Chapter 10, recommendations are made regarding requirements of a high-quality surgical service and how these standards can be measured Many patients with early lung cancer will not be fit for curative surgery owing to co-morbidities and recommendations are made for the use of stereotactic ablative radiotherapy (SABR) which utilises newly developed imaging and planning techniques to more precisely target treatment with highly ablative doses whilst minimising tissue toxicity This technique is described in some detail in Chapter 11 For more advanced, but potentially curable disease other radical treatments are described in Chapter 12 using concomitant or sequential chemo-radiotherapy or radiotherapy alone, and recommendations are made for follow-up of this group Chapter 13 explains that chemotherapy for metastatic non-small cell lung cancer is recommended in accordance with NICE guidance and therapies recommended by the Cancer Drugs Fund Palliative radiotherapy is recommended in some situations for symptom control The management of small cell lung cancer, Chapter 14, is largely unchanged, though there are recommendations for oral topotecan second line Chemotherapy regimes are listed in the appendices In Chapters 16 and 17, the guidelines cover the role of the lung cancer specialist nurse in supporting the patient and helping to provide a holistic needs assessment (HNA) at various stages of diagnosis and treatment The role of the nurse in providing information for patients and carers so that they can cope with the illness, and then deal with the consequences and long term side effects of the treatment as survivors is also discussed As the majority of patients with lung cancer present with their disease in an advanced stage, palliative treatment of these patients is important to improve their quality of life, and in Chapter 17 this is considered in some detail, particularly in relation to some advances in specific therapies Some of the recommendations in these guidelines will be challenging to implement, but as the role of the LCA is to ensure that world class quality of care is delivered for its patients with cancer, it is anticipated that provider organisations within the LCA will use these guidelines as a tool to support change improvement During the coming months the clinicians will develop standards and measures against which organisations can be assessed PREVENTION Prevention More than 80% of deaths from lung cancer are attributable to smoking Measures to prevent people from taking up smoking, or helping them to quit, will reduce the number of deaths from lung cancer In addition, patients with lung cancer undergoing curative treatment who stop smoking pre-treatment reduce the risk of complications from surgery 1.1 Background information Adult smoking prevalence is 21% and varies significantly by gender and socio-economic group Rates are higher in males than females and in more socio-economic deprived groups People in routine and manual occupations are about twice as likely to smoke as those in managerial or professional occupations (29% compared with 14%) (NHS Information Centre 2010) Incidence rates of lung cancer closely reflect past smoking prevalence with a time lag of approximately 20 to 30 years Smoking prevalence has decreased over the past 50 years and this accounts for the decrease in the rates of lung cancer Individuals who use NHS Stop Smoking Services have higher quit rates at one year than those receiving no intervention (Bauld et al 2009; Ferguson et al 2005) In addition, evidence suggests that brief interventions by healthcare professionals can increase the uptake of smoking cessation (NICE 2006) The provision of effective smoking cessation services in an acute Trust setting remains highly variable despite evidence that delivering smoking cessation interventions to inpatients in hospital is effective (Rigotti et al 2008) This is clearly a missed opportunity to deliver stop smoking interventions at a point at which an individual may be more susceptible to health advice and hence more motivated to quit The Department of Health (DH) has published a number of guidance documents on the development of smoking cessation services in an acute setting The key document for acute Trusts is Stop Smoking Interventions in Secondary Care In addition, DH has commissioned NCSCT (National Centre for Smoking Cessation and Training) to support and develop Stop Smoking Services across all healthcare settings Work undertaken by NCSCT demonstrates that the majority of inpatients who smoke are not receiving interventions to support them to stop smoking during their hospital stay The main barriers to successful implementation tend to be administrative elements such as data collection Lack of support from the Trust was also commonly cited as a barrier to implementing interventions 1.2 Smoking cessation services Provision of effective smoking cessation programmes is necessary to reduce the prevalence of smoking Smoking cessation interventions must be targeted to reach different population groups and provided across a range of settings In particular, there has been an increased focus on the need to establish effective smoking cessation services in secondary care (Fiore et al 2012) In 2009, DH published Stop Smoking Interventions in Secondary Care in an attempt to address the gap in service provision of smoking cessation in the acute setting LCA LUNG CANCER CLINICAL GUIDELINES Published evidence suggests that the necessary components for effective smoking cessation in secondary care are: a systematic process to identify and record patients who smoke staff trained to deliver ‘very brief advice’ prescription of nicotine replacement products – a range of these products must be available in the hospital formulary a referral system to local smoking cessation services – best practice is an electronic referral system The supporting processes identified to implement a successful smoking cessation programme for inpatients are: engaging with key stakeholders in the Trust training of staff in brief interventions – the NCSCT provides a free online training module developing patient information leaflets standardising the process for the identification of smokers setting up a referral process ensuring that a range of nicotine replacement therapies are available in the hospital formulary developing appropriate documentation to support the process developing a letter for the patient’s GP 1.3 Implementation of smoking cessation guidance The implementation of this guidance for clinicians treating patients with lung cancer at the earliest opportunity should improve outcomes (Moller et al 2002) It is advisable for patients undergoing surgery to have ceased smoking for a month before the operation rather than immediately beforehand, though it is not recommended that surgery is delayed because patients continue to smoke There are suggestions that other treatments for lung cancer are more effective if patients are no longer smoking, and for patients who have undergone radical treatment it may reduce the risk of a second tumour 10 LCA LUNG CANCER CLINICAL GUIDELINES Notes According to the NICE supportive and palliative care guidance, a key worker is a person who, with the patient’s consent and agreement, takes a key role in coordinating the patient’s care and promoting continuity, e.g ensuring that the patient knows who to access for information and advice This is not intended to have the same connotation as the key worker in social work It may be necessary to agree a single key worker across both a cancer site-specific MDT and the specialist palliative care MDT for certain patients October 2013 80 APPENDIX 7: LCA HOLISTIC NEEDS ASSESSMENT TOOL Appendix 7: LCA Holistic Needs Assessment Tool Care Plan During my holistic needs assessment, these issues were identified and discussed: Preferred name: Number Issue Example Breathlessness Hospital/NHS number: Summary of discussion Actions required/by (name and date) Possible causes identified Coping strategies discussed Printed information provided Referral to anxiety management programme; CNS to complete by 24th Dec Other actions/outcomes e.g d a editional information i g ven,r h alth po motion, smoking cessation, ‘My actions’: Signed (patient): Signed (healthcare professional): For health professional use Date of diagnosis: Date: Date: Diagnosis: Pathway point: 81 LCA LUNG CANCER CLINICAL GUIDELINES Appendix 8: NCSI Treatment Summary GP Name GP Address Dear Dr X Re: Add in patient name, address, date of birth and record number Your patient has now completed their initial treatment for cancer and a summary of their diagnosis, treatment and on-going management plan are outlined below The patient has a copy of this summary Diagnosis: Date of Diagnosis: Organ/Staging Local/Distant Summary of Treatment and relevant dates: Treatment Aim: Possible treatment toxicities and / or late effects: Advise entry onto primary care palliative or supportive care register Yes / No DS 1500 application completed Yes/No Prescription Charge exemption arranged Yes/No Alert Symptoms that require referral back to specialist team: Contacts for re referrals or queries: In Hours: Out of hours: Other service referrals made: (delete as nec) District Nurse AHP Secondary Care Ongoing Management Plan: (tests, appointments etc) Social Worker Dietician Clinical Nurse Specialist Psychologist Benefits/Advice Service Other Required GP actions in addition to GP Cancer Care Review (e.g ongoing medication, osteoporosis and cardiac screening) Summary of information given to the patient about their cancer and future progress: Additional information including issues relating to lifestyle and support needs: Completing Doctor: Signature: Date: 82 APPENDIX 8: NCSI TREATMENT SUMMARY GP READ CODES FOR COMMON CANCERS (For GP Use only) Other codes available if required (Note: System codes are case sensitive so always ensure codes are transcribed exactly as below) System (5 digit codes) Diagnosis: Lung Malignant Tumour XaOKG Carcinoma of Prostate Malignant tumour of rectum Bowel Intestine Large Bowel X78Y6 XE1vW X78gK X78gN Female Malignant Neoplasia Male Malignant Neoplasia Histology/Staging/Grade: Histology Abnormal Tumour grade Dukes/Gleason tumour stage Recurrent tumour Local Tumour Spread Mets from 1° Treatment Palliative Radiotherapy Curative Radiotherapy Chemotherapy Radiotherapy Treatment Aim: Curative procedure Palliative procedure Treatment toxicities/late effects: Osteoporotic # Osteoporosis Infection Ongoing Management Plan Follow up arranged (1yr) No FU Referral PRN Referrals made to other services: District Nurse Social Worker Nurse Specialist SALT B34 B35 4K14 X7A6m XaOLF XaOR3 X7818 XaFr 5149 XalpH x71bL Xa851 Xallm XaiL3 Xa1TO XaELC Xa9ua 8H8 XaL 8HA1 8HAZ All other systems Diagnosis Malignant neoplasm lung Malignant neoplasm Malignant neoplasm Malignant neoplasm Malignant neoplasm breast Malignant neoplasm Version five byte codes (October 2010 release) of bronchus or B22z of prostate of Rectum of Colon of female B46 B141 B13 B34 of male breast B35 Histology/Staging/Grade: Histology Abnormal Tumour staging Gleason grading of prostate Ca Recurrence of tumour Metastatic NOS Treatment Radiotherapy tumour palliation Radiotherapy Chemotherapy 4K14 4M… 4M0 4M6 BB13 5149 7M371 8BAD Treatment Aim: Curative treatment Palliative treatment 8BJ0 8BJ1 At risk of osteoporosis Osteoporosis 1409 N330 Ongoing Management Plan Follow up arranged 8H8 No follow up arranged 8HA Referrals made to other services: XaBsn XaBsr XaAgq XaBT6 Refer to District Nurse Refer to Social Worker 83 8H72 8H75 LCA LUNG CANCER CLINICAL GUIDELINES Actions required by the GP Tumour marker monitoring PSA Osteoporosis monitoring Referral for specialist opinion Advised to apply for free prescriptions Cancer Care Review Palliative Care Review Medication: New medication started by specialist Medication changed by specialist Advice to GP to start medication Advice to GP to stop medication Information to patient: DS1500 form claim Benefits counselling Cancer information offered Cancer diagnosis discussed Aware of diagnosis Unaware of prognosis Carer aware of diagnosis Miscellaneous: On GSF palliative care framework GP OOH service notified Carers details Actions required by the GP Tumour marker monitoring PSA Osteoporosis monitoring 8A9 43Z2 66a Entitled to free prescription 6616 8BAV 8CM3 XEOhn Cancer Care Review Palliative Care Plan Review Medication: Medication given 8B316 Medication changed 8B316 Information to patient: DS1500 completed Benefits counselling Cancer information offered Cancer diagnosis discussed 9EB5 6743 677H 8CL0 XaJv2 Miscellaneous: On GSF Palliative Care Framework 8CM1 Xaltp 9180 GP OOH service notified Carer details 9e0 9180 Xalqg Xalqh XalSd Xalst 9D05 Xalyc XalG1 8BC2 XaKbF XaJC2 XaCDx 6743 XalmL XalpL XaQly XaVzE XaVzA 84 APPENDIX 9: LUNG PATHWAY METRICS Appendix 9: Lung Pathway Metrics 85 LCA LUNG CANCER CLINICAL GUIDELINES Appendix 10: Treatment of Teenagers and Young Adults Treatment for patients from the age of 16 to their 25th birthday should be in line with national guidance regarding the management of teenagers and young adults with cancer Patients from the age of 16 to the end of their 18th year should be treated in the principal treatment centre Teenagers and young adults (TYA) from the age of 19 to their 25th birthday will follow the adult pathway but should be offered choice of treatment in a TYA-designated hospital or at the principal treatment centre TYAs in this age group should be treated either in the principal treatment centre or a designated hospital The principal treatment centre for South Thames is The Royal Marsden NHS Foundation Trust The North West London TYA principal treatment centre is University College London Hospitals NHS Foundation Trust Principal treatment centre contacts Lead Clinician – Julia Chisholm julia.chisholm@rmh.nhs.uk The Royal Marsden NHS Foundation Trust TCT Nurse Consultant for Adolescents and Young Adults – Louise Soanes lsoanes@nhs.net Lead Clinician – Rachael Hough rachael.hough@uclh.nhs.uk University College London Hospitals TCT Nurse Consultant – Wendy King wendy.king@uclh.nhs.uk 86 APPENDIX 10: TREATMENT OF TEENAGERS AND YOUNG ADULTS TYA-designated centre contacts Joint Centre (Guy’s and St Thomas’ NHS Foundation Trust/King’s College Hospital NHS Foundation Trust) Joint Centre (Guy’s and St Thomas’ NHS Foundation Trust/King’s College Hospital NHS Foundation Trust) St George’s Healthcare NHS Trust Chelsea and Westminster Hospital NHS Foundation Trust Imperial College Healthcare NHS Trust East and North Hertfordshire NHS Trust Lead Clinician – Robert Carr robert.carr@gstt.nhs.uk Guy’s and St Thomas’ Lead Nurse – Gavin Maynard-Wyatt gavin.maynard-wyatt@gstt.nhs.uk Lead Clinician – Donal.Mclornan donal.mclornan@nhs.net King’s College Hospital Lead Nurse – Gavin Maynard-Wyatt Gavin.maynard-wyatt@gstt.nhs.uk Lead Clinician – Jens Samol jens.samol@stgeorges.nhs.uk St George’s Hospital Lead Nurse – Linda Shephard linda.shephard@stgeorges.nhs.uk Lead Clinician – Mark Bower (interim) mark.bower@chelwest.nhs.uk Chelsea and Westminster (HIV and skin only) Lead Nurse – Kate Shaw (interim) kate.shaw@chelwest.nhs.uk Lead Clinician – Josu de la Fuente (deputy) j.delafuente@imperial.ac.uk Charing Cross Lead Nurse – Sinead Cope sinead.cope@imperial.nhs.uk Lead Clinician – Gordon Rustin grustin@nhs.net Mount Vernon Cancer Centre Lead Nurse – Laura Miles laura.miles@nhs.net 87 LCA LUNG CANCER CLINICAL GUIDELINES Abbreviations 2ww week wait 4-D Four-dimensional ABC Active breathing control BTS British Thoracic Society CNS Clinical nurse specialist COPD Chronic obstructive pulmonary disease CT Computerised tomography CTCAE Common Terminology Criteria for Adverse Events (formerly known as the Common Toxicity Criteria) CTV Clinical target volume CXR Chest X-ray DH Department of Health DVH Dose-volume histogram EBUS Endobronchial ultrasound ECG Electrocardiogram EGFR Epidermal growth factor receptor ERAS Enhanced recovery after surgery FBC Full blood count FEV1 Forced expiratory volume in one second FNA Fine needle aspiration FVC Forced vital capacity GP General practitioner GTV Gross tumour volume Gy Gray HNA Holistic needs assessment IGRT Image guided radiotherapy ITV Internal target volume IV Intravenous LCA London Cancer Alliance LFT Liver function test MDM Multidisciplinary meeting MDT Multidisciplinary team MRI Magnetic resonance imaging NCSCT NHS Centre for Smoking Cessation and Training 88 ABBREVIATIONS NCSI National Cancer Survivorship Initiative NICE National Institute for Health and Care Excellence NLCFN National Lung Cancer Forum for Nurses NSCLC Non-small cell lung cancer OAR Organ at risk PET Positron emission tomography PRV Planning organ at risk volume PS Performance status PTTA Percutaneous thermal tumour ablation PTV Planning target volume RCPath Royal College of Pathologists SABR Stereotactic ablative radiotherapy SCLC Small cell lung cancer SRS Stereotactic radiosurgery SVC Superior vena cava TBNA Transbronchial needle aspiration TKI Tyrosine kinase inhibitor TLCO Total gas transfer of the lung for carbon monoxide UEC Urea, electrolytes and creatinine WHO World Health Organization 89 LCA LUNG CANCER CLINICAL GUIDELINES References American Thoracic Society/European Respiratory Society (2006) Statement on Pulmonary Rehabilitation Aupérin A, Lé Pechoux C, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer Journal of Clinical Oncology 28(13): 2181–90 Bauld L, Bell K, McCullough L et al (2009) The effectiveness of NHS smoking cessation services: a systematic review Journal of Public Health 32(1): 71–82 Delgado-Rodriguez M, Medina-Cuadros M, Martinez-Gallego G et al (2003) A prospective study of tobacco smoking as a predictor of complications in general surgery Infection Control & Hospital Epidemiology 24(1): 37–43 Department of Health (DH) (2009) Stop Smoking Interventions in Secondary Care London: DH DH (2010) National Cancer Survivorship Initiative: Vision London: DH DH (2011) Improving Outcomes: a strategy for cancer London: DH DH (2013) Living With and Beyond Cancer: Taking Action to Improve Outcomes London: DH Ferguson J, Bauld L, Chesterman J et al (2005) The English smoking treatment services – one-year outcomes Addiction 100(suppl 2): 59–69 Fiore M, Goplereud E, Schroeder S (2012) The Joint Commission’s New Tobacco-Cessation Measures – Will Hospitals Do the Right Thing New England Journal of Medicine 336(13): 1172–1174 Fleisher LA et al (2007) ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery, Circulation 116: e418–e500 Hurkmans CW, Cuijpers JP, Lagerwaard FJ et al (2009) Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study Radiation Oncology 4:1 International Association for the Study of Lung Cancer (IASLC) (2009) [lymph node dissection] Lee SM et al (2009) Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer, Thorax 64(1): 75–80 PMID: 18786981 Lim E et al (2010) ‘Guidelines on the radical management of patients with lung cancer’, Thorax 65 Suppl 3: 1–27 Lim WS and Woodhead M/BTS (2011) British Thoracic Society adult community acquired pneumonia audit 2009/10, Thorax 66(6): 548–549 PMID: 21502103 London Cancer Alliance (2012) The Future of Lung Cancer Thoracic Surgery in the London Cancer Alliance London Cancer Alliance (2013) LCA Acute Oncology Clinical Guidelines, www.londoncanceralliance.nhs.uk/news,-events-resources/news/2013/09/lca-publishes-new-acuteoncology-clinical-guidelines/ Moller A, Villebro N, Pederson T and Tonnesen H (2002) Effect of preoperative smoking intervention on post-operative complications: a randomised control trial Lancet 359(9301): 114–7 90 REFERENCES NCSCT (2011) Stop Smoking Interventions in Secondary Care: pre-implementation report 2011 NHS Information Centre (2010) Statistics on Smoking: England 2010 Leeds: NHS Information Centre NICE (2004) Improving supportive and palliative care for adults with cancer CSGSP NICE (2004) Supportive and palliative care: the Manual NICE (2005) Lung cancer: diagnosis and treatment CG24 NICE (2005) Referral guidelines for suspected cancer CG27 NICE (2006) Nutrition support in adults: oral nutrition support, enteral tube feeding and parenteral nutrition CG32 NICE (2006) Brief interventions and referral for smoking cessation PHG1 NICE (2008) Smoking cessation services in primary care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities PHG10 NICE (2009) Lung cancer (non-small-cell, first line treatment) – pemetrexed TA181 NICE (2009) Lung cancer (small-cell) – topotecan TA184 NICE (2010) Lung cancer (non-small-cell) – pemetrexed (maintenance) TA190 NICE (2010) Lung cancer (non-small-cell, first line) – gefitinib TA192 NICE (2011) The diagnosis and treatment of lung cancer CG121 NICE (2012) Lung cancer for adults QS17 NICE (2012) Lung cancer (non small cell, EGFR-TK mutation positive) – erlotinib (1st line) TA258 NICE (2012) Lung cancer (non-small-cell) – erlotinib: review decision TA162 NICE (2013, forthcoming) Smoking cessation in secondary care – acute and maternity services National Lung Cancer Forum for Nurses (NLCFN) (2004) Integrating Lung Cancer Nursing: A Good Practice Guide NLCFN (2012) Guidance for the supportive and palliative care of lung cancer and mesothelioma patients and their families Rigotti NA, Munafo MR and Stead LF (2007) Interventions for smoking cessation in hospitalised patients Cochrane Database Systems Review 18(3) Royal College of Pathologists (RCPath) (2011) Data set for lung cancer histopathology report (3rd edition) Vincent M et al (1988) First-line chemotherapy rechallenge after relapse in small cell lung cancer, Cancer Chemotherapy and Pharmacology 21(1); 45–48 PMID: 2830043 World Cancer Research Fund (WCRF) (2007) WCRF/AICR's Second Expert Report, Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective 91 LCA LUNG CANCER CLINICAL GUIDELINES Acknowledgements Our thanks to the following healthcare professionals, patients and carers who have provided input into the LCA Lung Cancer Clinical Guidelines: Pathway Group members Dr Liz Sawicka, LCA Lung Pathway Group Chair, Consultant Chest Physician, Princess Royal University Hospital Dr Tuck-Kay Loke, Consultant Respiratory Physician, Croydon University Hospital Vivien Bruce, Lung Cancer Clinical Nurse Specialist, Croydon University Hospital Jane Lynch, Lung Cancer Clinical Nurse Specialist, Imperial College Healthcare NHS Trust Dr Sanjay Popat, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust Professor Andrew Nicholson, Consultant Histopathologist and Head of Histopathology, Royal Brompton & Harefield NHS Foundation Trust Mr Simon Jordan, Consultant Thoracic Surgeon, Royal Brompton &Harefield NHS Foundation Trust Dr Pawan Randev, GP Lead, North and West London CCT Dr Anthony Cunliffe, Macmillan GP Facilitator, Cancer Commissioning Lead for Wandsworth, NHS Wandsworth CCG Dr Paul Cane, Consultant Histopathologist and Lead for Lung Cancer, Guy’s & St Thomas’ NHS Foundation Trust Dr Kate Haire, Consultant in Public Health and LCA Lead for Clinical Commissioning Miss Carol Tan, Consultant Thoracic Surgeon, St George’s Healthcare NHS Trust Mr Paras Dalal, Consultant Cardio-thoracic Radiologist, Royal Brompton & Harefield NHS Foundation Trust Dr Shahreen Ahmad, Consultant Clinical Oncologist, Guy’s and St Thomas’ NHS Foundation Trust Dr Rohit Lal, Consultant Medical Oncologist, Guy’s and St Thomas’ NHS Foundation Trust Dr Anand Devaraj, Consultant Radiologist, St George’s Healthcare NHS Trust Dr Fiona McDonald, Consultant Clinical Oncologist, The Royal Marsden NHS Foundation Trust Dr Mary O’Brien, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust Dr Tom Newsom-Davis, Consultant Medical Oncologist and LCA AOS Pathway Chair, Chelsea and Westminster Hospital NHS Foundation Trust Scott Mitchell, Pharmacist, The Royal Marsden NHS Foundation Trust Dr Danielle Power, Consultant Clinical Oncologist, Imperial College Healthcare NHS Trust Rhys White, Principal Oncology Dietitian, Guy’s and St Thomas’ NHS Foundation Trust Dr Russell Moule, Consultant Clinical Oncologist, Mount Vernon Cancer Centre Other contributing healthcare professionals Dr Nigel Sykes, Consultant in Palliative Care and Medical Director, St Christopher’s Hospice 92 ACKNOWLEDGEMENTS Patient and carer representatives Malcolm Levene, Lung Cancer Patient Representative John Robinson, Carer Representative LCA project managers Victoria Harrison, Lung Project Manager Stephen Scott, Senior Informatics Manager Nicola Glover, Survivorship Project Manager 93 © London Cancer Alliance 2013 Published by London Cancer Alliance London Cancer Alliance 5th Floor Alliance House 12 Caxton Street London SW1H 0QS www.londoncanceralliance.nhs.uk [...]... advanced communication skills 25 LCA LUNG CANCER CLINICAL GUIDELINES 7 Data Requirements of Lung Cancer Services Lung cancer services within the LCA are required to submit data to nationally mandated datasets for patients diagnosed with lung cancer These are as follows: 7.1 The Cancer Outcomes and Services Dataset (COSD) The core dataset for all tumour types including lung cancer is mandated from January... suggestive of brain metastases (see Figure 3.1) Figure 3.1: Investigations to stage lung cancer 17 LCA LUNG CANCER CLINICAL GUIDELINES 3.5 Staging of lung cancer The TNM Classification of Malignant Tumours, 7th edition, is used to stage lung cancer Radiological staging should be included in the report on a staging CT scan Final staging (prior to mediastinal sampling) should be a combined decision made... the abdominal organs where lung cancer commonly spreads, i.e liver and adrenal glands.) 13 LCA LUNG CANCER CLINICAL GUIDELINES 3.2 Assessment of patients with possible lung cancer for investigation 3.2.1 Presentation The following factors are assessed and recorded at the first outpatient appointment in patients presenting with possible lung cancer History including: age previous/current occupation... the adoption of the National Cancer Survivorship Initiative (NCSI) Treatment Summary A copy of this document can be found at Appendix 8 31 LCA LUNG CANCER CLINICAL GUIDELINES 10 Surgical Guidelines 10.1 Introduction The LCA adopts the British Thoracic Society (BTS) guidelines (Lim et al 2010) on the surgical management of patients with lung cancer 10.2 Non-small cell lung cancer 10.2.1 Patient selection... working diagnosis of lung cancer The team should include the following: a respiratory physician with a special interest in lung cancer a radiologist with thoracic expertise a pathologist +/- a cytologist a lung cancer specialist nurse an oncologist, preferably with a specialist interest in lung cancer: either a clinical oncologist or a medical oncologist working closely with a clinical oncologist... decisions and referrals may already have been planned, thus pre-empting the results 22 PATHOLOGY GUIDELINES FOR THE REPORTING OF LUNG CANCER 5 Pathology Guidelines for the Reporting of Lung Cancer The LCA follows the minimum dataset recommendations of the Royal College of Pathologists (RCPath) 5.1 Biopsies for lung cancer According to local policy, biopsies may or may not be fast tracked Specimen request... regular 6-monthly CXR with telephone follow-up by the lung CNS It is not known whether imaging during follow-up improves outcomes by detecting recurrence or a further primary earlier, and trials should be conducted to look into this 35 LCA LUNG CANCER CLINICAL GUIDELINES 10.10 LCA high-quality lung cancer surgical service – measures and metrics The LCA Lung Pathway Group, in conjunction with surgeons from... processing based on local policy Full clinical details should be provided (in particular, history of previous malignancy), and if necessary further data should be obtained from the requesting clinician Specimens are processed as indicated in the RCPath guidelines (Dataset for Lung Cancer Histology Reports www.rcpath.org/publications-media/publications/datasets /lung. htm) 5.2 Lung resection for tumours These... activity took place 7.2 National Audits – National Clinical Lung Cancer Audit (LUCADA) The LUCADA audit has been up and running since 2004, and requires Trusts to submit data for patients diagnosed with lung cancer The details of the dataset can be found on the Health & Social Care Information Centre website at www.hsic.gov.uk /lung 7.3 Systemic Anti -Cancer Therapy (SACT) chemotherapy dataset Trusts... collating information from the various sources of data available, though the Lung Pathway Group or LCA Clinical Board may require Trusts to submit additional MDT data to the LCA if additional priority areas are identified 27 LCA LUNG CANCER CLINICAL GUIDELINES 8 Breaking Bad News Staff dealing with patients and giving diagnoses of cancer should have received training in advanced communication skills Bad ... Investigations to stage lung cancer 17 LCA LUNG CANCER CLINICAL GUIDELINES 3.5 Staging of lung cancer The TNM Classification of Malignant Tumours, 7th edition, is used to stage lung cancer Radiological... set of guidelines is limited to small cell, non-small cell lung cancer, and carcinoid Separate clinical guidelines will be developed for mesothelioma and thymoma LCA LUNG CANCER CLINICAL GUIDELINES. .. abdominal organs where lung cancer commonly spreads, i.e liver and adrenal glands.) 13 LCA LUNG CANCER CLINICAL GUIDELINES 3.2 Assessment of patients with possible lung cancer for investigation